Theravance's TD-9855 improves symptom severity in Phase II for hypotension

Theravance Biopharma Inc. (NASDAQ:TBPH) reported data from 16 patients with symptomatic neurogenic orthostatic hypotension in Part C of a Phase II trial showing that once-daily TD-9855 led to a mean symptom improvement of 2.4 points in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 score at week four. Additionally, more than 60% of patients achieved a ≥2-point improvement on the endpoint. OHSA Question #1 measures patients' dizziness, lightheadedness, feeling faint or feeling like they might black out.

In 13 patients who had a baseline OHSA Question #1 score of ≥4 points, TD-9855 led to a mean symptom improvement of 3.8 points on the endpoint...